Amplia’s Chief Scientific Officer, Dr Mark Devlin, recently caught up with Kerry Stevenson from Small Caps to discuss the Company’s current capital raise, and plans to progress AMP945 to Phase 2 clinical trials in first-line pancreatic cancer patients in the New Year.
Last week, Amplia released supplementary findings from the Phase 1 clinical trial of AMP945 in healthy volunteers, which confirmed that orally administered AMP945, at safe and well-tolerated doses, selectively inhibits its intended target protein, Focal Adhesion Kinase (FAK).
In describing the study, Dr Devlin said:
“This has confirmed our best expectations...a lot of companies don’t have that confidence when moving from a Phase 1 trial into a Phase 2, so for us, this supplementary finding gives us confidence moving into those patient trials next year. This is a really exciting time for the company, and Amplia’s current $12 million cap raise puts us in a very strong position.”
Watch the interview